MA39722A - Composition pour son utilisation dans une methode de traitement ou de prevention de l'anemie par l'inhibition de l'activine b et du gdf11 - Google Patents

Composition pour son utilisation dans une methode de traitement ou de prevention de l'anemie par l'inhibition de l'activine b et du gdf11

Info

Publication number
MA39722A
MA39722A MA039722A MA39722A MA39722A MA 39722 A MA39722 A MA 39722A MA 039722 A MA039722 A MA 039722A MA 39722 A MA39722 A MA 39722A MA 39722 A MA39722 A MA 39722A
Authority
MA
Morocco
Prior art keywords
gdf11
activin
anemia
inhibition
prevention
Prior art date
Application number
MA039722A
Other languages
English (en)
French (fr)
Inventor
John Knopf
Ravindra Kumar
Naga Venkata Sai Rajasekhar Suragani
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of MA39722A publication Critical patent/MA39722A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA039722A 2014-03-21 2015-03-20 Composition pour son utilisation dans une methode de traitement ou de prevention de l'anemie par l'inhibition de l'activine b et du gdf11 MA39722A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461969073P 2014-03-21 2014-03-21
US201462021923P 2014-07-08 2014-07-08

Publications (1)

Publication Number Publication Date
MA39722A true MA39722A (fr) 2021-06-02

Family

ID=54145413

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039722A MA39722A (fr) 2014-03-21 2015-03-20 Composition pour son utilisation dans une methode de traitement ou de prevention de l'anemie par l'inhibition de l'activine b et du gdf11

Country Status (9)

Country Link
US (2) US20160046690A1 (enExample)
EP (1) EP3119418B1 (enExample)
JP (2) JP2017509647A (enExample)
KR (2) KR20160127148A (enExample)
CN (1) CN106659769A (enExample)
AU (3) AU2015231022B2 (enExample)
CA (1) CA2942954A1 (enExample)
MA (1) MA39722A (enExample)
WO (1) WO2015143403A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
RU2678117C2 (ru) 2012-11-02 2019-01-23 Селджин Корпорейшн Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
AU2015339134B2 (en) 2014-10-30 2021-06-17 Acceleron Pharma Inc. Methods and compositions using GDF15 polypeptides for increasing red blood cells
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
EP3227675B1 (en) 2014-12-03 2023-03-15 Celgene Corporation Activin-actrii antagonists and uses for treating myelodysplastic syndrome
CA2983440C (en) 2015-04-22 2024-03-12 Alivegen Usa Inc. Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases
EP3370754B1 (en) 2015-11-04 2026-04-29 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
JP7072507B2 (ja) 2015-11-23 2022-05-20 アクセルロン ファーマ インコーポレイテッド 眼の障害を処置するための方法
LT3490582T (lt) 2016-07-27 2024-07-25 Acceleron Pharma Inc. Kompozicijos, skirtos naudoti gydant mielofibrozę
WO2018053234A1 (en) * 2016-09-15 2018-03-22 Acceleron Pharma, Inc. Twisted gastrulation polypeptides and uses thereof
AU2017338916B2 (en) * 2016-10-05 2022-03-24 Acceleron Pharma Inc. Variant ActRIIB proteins and uses thereof
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
CA3043184A1 (en) 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
WO2018231905A1 (en) 2017-06-14 2018-12-20 Celgene Corporation Methods for treating myeloproliferative neoplasm-associated myelofibrosis and anemia
CN107828719B (zh) * 2017-09-14 2020-05-19 暨南大学 Gdf11在脂肪间充质干细胞成骨分化中的应用
EP3706777B1 (en) 2017-11-09 2024-05-22 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
IL320014A (en) 2018-01-12 2025-06-01 Keros Therapeutics Inc Activin receptor type iib variants and methods of use thereof
WO2019213016A1 (en) * 2018-04-30 2019-11-07 The Children's Hospital Of Philadelphia Methods of improving anemias by combining agents
IL278546B2 (en) 2018-05-09 2026-03-01 Keros Therapeutics Inc Activin receptor type IIA variants and methods of using them
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
EP4121078A4 (en) 2020-03-20 2024-08-14 Keros Therapeutics, Inc. ACTIVIN RECEPTOR TYPE II CHIMERAS AND METHODS OF USE THEREOF
EP4514971A4 (en) * 2022-04-29 2026-06-03 Univ Massachusetts SELECTIVE RNA MODULATION AGENTS
WO2025040002A1 (zh) * 2023-08-21 2025-02-27 苏州炫景生物科技有限公司 靶向inhbe基因的双链寡核苷酸、缀合物、组合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200724548A (en) * 2005-04-25 2007-07-01 Pfizer Antibodies to myostatin
US8128933B2 (en) * 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
CA2672758C (en) * 2006-12-18 2019-07-30 Acceleron Pharma Inc. Activin-actrii antagonists and uses for increasing red blood cell levels
DK3750552T5 (da) * 2008-08-14 2024-08-26 Acceleron Pharma Inc Gdf-fælder
US8216997B2 (en) * 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
MX355042B (es) * 2009-06-08 2018-04-02 Acceleon Pharma Inc Metodos para aumentar adipositos termogenicos.
KR102170682B1 (ko) 2009-08-13 2020-10-28 악셀레론 파마 인코포레이티드 적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용
WO2012027065A2 (en) * 2010-08-27 2012-03-01 Celgene Corporation Combination therapy for treatment of disease
DK3520805T3 (da) * 2011-10-17 2021-04-19 Acceleron Pharma Inc Sammensætninger til behandling af myelofibrose
EP2844668A1 (en) * 2012-05-03 2015-03-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment and diagnotic of anemia of inflammation
JP6401172B2 (ja) * 2012-10-24 2018-10-10 セルジーン コーポレイション 貧血の治療方法

Also Published As

Publication number Publication date
US20210155672A1 (en) 2021-05-27
EP3119418B1 (en) 2022-02-23
US20160046690A1 (en) 2016-02-18
EP3119418A4 (en) 2018-01-03
AU2015231022A1 (en) 2016-09-29
WO2015143403A1 (en) 2015-09-24
CN106659769A (zh) 2017-05-10
KR20230004942A (ko) 2023-01-06
KR20160127148A (ko) 2016-11-02
JP7154250B2 (ja) 2022-10-17
EP3119418A1 (en) 2017-01-25
KR102520970B1 (ko) 2023-04-12
JP2020111621A (ja) 2020-07-27
AU2021200301A1 (en) 2021-03-18
JP2017509647A (ja) 2017-04-06
AU2015231022B2 (en) 2021-02-04
AU2023219885A1 (en) 2023-09-14
CA2942954A1 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
EP3374502A4 (en) METHOD FOR THE TREATMENT OF CORNEAL DYSTROPHIES
EP3302379A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF PTERYGIUM
EP3347469A4 (en) METHOD AND COMPOSITIONS FOR TREATING GLAUCOMA
EP3368559A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
EP3233878A4 (en) PHOSPHORAMIDATE FOR THE TREATMENT OF HEPATITIS C VIRUS
EP3390642A4 (en) COMPOSITIONS AND METHODS OF TREATING RETINITIS PIGMENTOSA 18 AND RETINITIS PIGMENTOSA 13
EP3380200A4 (en) COMPOSITIONS FOR TREATING THE HAIR
EP3341391A4 (en) COMPOSITIONS AND METHODS OF PAIN TREATMENT
EP3377516A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP3362065A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF MALIGNITIES
EP3503890A4 (en) USE OF PRIDOPIDIN FOR THE TREATMENT OF DYSTONIA
EP2875824A4 (en) COMPOSITION FOR PREVENTING OR TREATING KACHEXIA
EP3380063A4 (en) COMPOSITIONS FOR TREATING THE HAIR
EP3334432A4 (en) CERDULATINIB FOR THE TREATMENT OF MYELOMA
EP3347025A4 (en) METHOD AND COMPOSITIONS FOR CANCER TREATMENT
EP3429609A4 (en) COMPOSITIONS AND METHOD FOR TREATING DEFECTS OF COLLAGEN TYPE VII
EP3353204A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
MA43230A (fr) Méthodes et compositions pour le traitement d'une épidermolyse bulleuse
EP3386967A4 (en) COMBINATIONS FOR TREATING KIDNEY STONES
EP3329929A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF DRY EYES
EP3522865A4 (en) METHOD AND COMPOSITIONS FOR TREATING STRIAE DISTENSAE
EP3331545A4 (en) FOR EXTRACELLULAR HEMICAN DOMAIN SPECIFIC MEANS FOR THE TREATMENT OF SEPSIS
EP3365014A4 (en) METHOD AND COMPOSITIONS FOR TREATING SYSTEMIC MASTO CYTOSIS
EP3386593A4 (en) IMMUNOMODULATING COMPOSITION FOR TREATMENT
MA45973A (fr) Combinaisons d'inhibiteurs de btk pour le traitement du myélome multiple